Literature DB >> 9195291

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action.

E A Woltering1, J C Watson, R C Alperin-Lea, C Sharma, E Keenan, D Kurozawa, R Barrie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9195291     DOI： 10.1023/a:1005774713202

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  24 in total

1.  Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome.

Authors:  W O Richards; R Geer; T M O'Dorisio; T Robarts; K L Parish; D Rice; G Woltering; N N Abumrad
Journal:  J Surg Res       Date:  1990-12       Impact factor: 2.192

2.  Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

Authors:  S R Bloom; C H Mortimer; M O Thorner; G M Besser; R Hall; A Gomez-Pan; V M Roy; R C Russell; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

3.  Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide.

Authors:  C A Hoefnagel; E M Rankin; R A Valdés Olmos; S P Israëls; S Pavel; A G Janssen
Journal:  Eur J Nucl Med       Date:  1994-06

4.  Protein kinase C is not essential for growth hormone (GH)-releasing factor-induced GH release from rat somatotrophs.

Authors:  M B French; B C Moor; B T Lussier; J Kraicer
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

5.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5.

Authors:  K Raynor; A M O'Carroll; H Kong; K Yasuda; L C Mahan; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

6.  Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.

Authors:  K Raynor; W A Murphy; D H Coy; J E Taylor; J P Moreau; K Yasuda; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

Review 7.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

8.  Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent.

Authors:  R Barrie; E A Woltering; H Hajarizadeh; C Mueller; T Ure; W S Fletcher
Journal:  J Surg Res       Date:  1993-10       Impact factor: 2.192

9.  Characterization of somatostatin receptors on human neuroblastoma tumors.

Authors:  M S O'Dorisio; F Chen; T M O'Dorisio; D Wray; S J Qualman
Journal:  Cell Growth Differ       Date:  1994-01

10.  Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas.

Authors:  G Weckbecker; L Tolcsvai; B Stolz; M Pollak; C Bruns
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701
View more
  22 in total

Review 1.  Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

2.  Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides.

Authors:  F Alderton; T P Fan; P P Humphrey
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

4.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

5.  A study of pipeline drugs in neuroendocrine tumors.

Authors:  Catherine T Anthony; Juan G Bastidas; Jessica L Thomson; John Lyons; James M Lewis; Joshua E Schwimer; Peter Casey; Jennifer Abadie; Daniel J Frey; Yi-Zarn Wang; J Philip Boudreaux; Eugene A Woltering
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 6.  The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 7.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

8.  Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.

Authors:  Jing-Hua Wang; Quan-Tai Xing; Meng-Biao Yuan
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

9.  Inhibition of experimental angiogenesis of cornea by somatostatin.

Authors:  Pei-Chang Wu; Chi-Chang Liu; Chih-hsin Chen; Hsi-Kung Kou; Su-Chin Shen; Cheng-Yuan Lu; Wen-Ying Chou; Ming-Tse Sung; Lin-Cheng Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-12-18       Impact factor: 3.117

Review 10.  Evolving treatment strategies for management of carcinoid tumors.

Authors:  Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.